[1] OUCHI N, PARKER J L, LUGUS J J, et al. Adipokines in inflammation and metabolic disease[J]. Nat Rev Immunol, 2011, 11(2):85-97.
[2] MATTU H S, RANDEVA H S. Role of adipokines in cardiovascular disease[J]. J Endocrinol, 2013, 216(1):T17-T36.
[3] SELDIN M M, TAN S Y, WONG G W. Metabolic function of the CTRP family of hormones[J]. Rev Endocr Metab Disord, 2014, 15(2):111-123.
[4] DAVIS K E, SCHERER P E. Adiponectin:no longer the lone soul in the fight against insulin resistance?[J]. Biochem J, 2008, 416(2):e7-e9.
[5] WONG G W, KRAWCZYK S A, KITIDIS-MITROKOSTAS C, et al. Molecular, biochemical and functional characterizations of C1q/TNF family members:adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions[J]. Biochem J, 2008, 416(2):161-177.
[6] WONG G W, WANG J, HUG C, et al. A family of Acrp30/adiponectin structural and functional paralogs[J]. Proc Natl Acad Sci U S A, 2004, 101(28):10302-10307.
[7] SCHÄFFLERA, BUECHLER C. CTRP family:linking immunity to metabolism[J]. Trends Endocrinol Metab, 2012, 23(4):194-204.
[8] FLEHMIG G, SCHOLZ M, KLÖTING N, et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation[J]. PLoS One, 2014, 9(6):e99785.
[9] SELDIN M M, PETERSON J M, BYERLY M S, et al. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis[J]. J Biol Chem, 2012, 287(15):11968-11980.
[10] WEI Z K, PETERSON J M, WONG G W. Metabolic regulation by C1q/TNF-related protein-13(CTRP13):activation OF AMP-activated protein kinase and suppression of fatty acid-induced JNK signaling[J]. J Biol Chem, 2011, 286(18):15652-15665.
[11] BYERLY M S, SWANSON R, WEI Z, et al. A central role for C1q/TNF-related protein 13(CTRP13) in modulating food intake and body weight[J]. PLoS One, 2013, 8(4):e62862.
[12] WONG G W, KRAWCZYK S A, KITIDIS-MITROKOSTAS C, et al. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin[J]. Faseb J, 2009, 23(1):241-258.
[13] KISHORE U, GABORIAUD C, WATERS P, et al. C1q and tumor necrosis factor superfamily:modularity and versatility[J]. Trends Immunol, 2004, 25(10):551-561.
[14] PAJVANI U B, HAWKINS M, COMBS T P, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity[J]. J Biol Chem, 2004, 279(13):12152-12162.
[15] PETERSON J M, SELDIN M M, TAN S Y, et al. CTRP2 overexpression improves insulin and lipid tolerance in diet-induced obese mice[J]. PLoS One, 2014, 9(2):e88535.
[16] SHANAKI M, FADAEI R, MORADI N, et al. The circulating CTRP13 in type 2 diabetes and non-alcoholic fatty liver patients[J]. PLoS One, 2016, 11(12):e0168082.
[17] BAI B, BAN B, LIU Z J, et al. Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose[J]. PLoS One, 2017, 12(2):e0172271.
[18] FADAEI R, MORADI N, BARATCHIAN M, et al. Association of C1q/TNF-Related protein-3(CTRP3) and CTRP13 serum levels with coronary artery disease in subjects with and without type 2 diabetes mellitus[J]. PLoS One, 2016, 11(12):e0168773.
[19] WANG C, XU W J, LIANG M L, et al. CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36[J]. FASEB J, 2019, 33(2):2290-2300.
[20] CARR M C, BRUNZELL J D. Abdominal obesity and dyslipidemia in the metabolic syndrome:importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk[J]. J Clin Endocrinol Metab, 2004, 89(6):2601-2607.
[21] AFROOKHTEH A, EMAMGHOLIPOUR S, ALIPOOR B, et al. The circulating levels of complement-C1q/TNF-related protein 13(CTRP13) in patients with type 2 diabetes and its association with insulin resistance[J]. Clin Lab, 2017, 63(2):327-333.
[22] DOWMAN J K, TOMLINSON J W, NEWSOME P N. Pathogenesis of non-alcoholic fatty liver disease[J]. QJM, 2010, 103(2):71-83.
[23] EMAMGHOLIPOUR S, MORADI N, BEIGY M, et al. The association of circulating levels of complement-C1q TNF-related protein 5(CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes:a case-control study[J]. Diabetol Metab Syndr, 2015, 7:108.
[24] AN K, STARKWEATHER A, STURGILL J, et al. Association of CTRP13 with liver enzymes and cognitive symptoms in nonalcoholic fatty liver disease[J]. Nurs Res, 2019, 68(1):29-38.
[25] YUASA D, OHASHI K, SHIBATA R, et al. Association of circulating C1q/TNF-related protein 1 levels with coronary artery disease in men[J]. PLoS One, 2014, 9(6):e99846.
[26] WANG H Z, WANG R, DU D Y, et al. Serum levels of C1q/TNF-related protein-1(CTRP-1) are closely associated with coronary artery disease[J]. BMC Cardiovasc Disord, 2016, 16:92.
[27] GALKINA E, LEY K. Immune and inflammatory mechanisms of atherosclerosis(*)[J]. Annu Rev Immunol, 2009, 27:165-197.
[28] HUANG J, QIAN H Y, LI Z Z, et al. Role of endothelial lipase in atherosclerosis[J]. Transl Res, 2010, 156(1):1-6.
[29] KOPP A, BALA M, BUECHLER C, et al. C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue[J]. Endocrinology, 2010, 151(11):5267-5278.
[30] WEIGERT J, NEUMEIER M, SCHÄFFLER A, et al. The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells[J]. FEBS Lett, 2005, 579(25):5565-5570. |
